
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurosci.
Sec. Neuropharmacology
Volume 19 - 2025 | doi: 10.3389/fnins.2025.1513135
This article is part of the Research Topic Neuropharmacological Intervention for Severe Mental Illness and Suicide Prevention View all 10 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Epilepsy is one of the most prevalent neurological disorders globally. Current treatments mainly target neuronal activity, often overlooking the involvement of astrocytes and microglia in epilepsy's pathophysiology. Here, we explored the impact of purinergic receptors, predominantly found in glial tissue, on epileptiform activity. We used TNP-ATP, a potent purinergic receptor antagonist, and conducted experiments using a mouse model of mesial temporal lobe epilepsy to examine behavioral performance and neural activity patterns. Our findings reveal that although TNP-ATP treatment did not significantly impact motor function or anxiety levels, it reduced both the amplitude and rate of hippocampal interictal discharges. Such reduction also affected the synchrony of associated neuronal spiking. Additionally, cognitive function, particularly hippocampus-dependent spatial memory and prefrontal cortex-dependent executive control, were partially restored. Moreover, neuronal recordings showed increased phase coherence between the hippocampus and prefrontal cortex for both slow (theta) and fast (gamma) oscillations in treated animals, indicating strengthened neural coordination between cortical regions upon purinergic receptor antagonism. These results underscore the potential role of purinergic receptor antagonists in improving behavioural and cognitive performance in epilepsy, providing novel insight into the use of these pharmacological agents as a therapeutic approach.
Keywords: purinergic receptor, Temporal Lobe Epilepsy, Interictal discharges, cognitive dysfunction, cortical oscillation
Received: 17 Oct 2024; Accepted: 19 Feb 2025.
Copyright: © 2025 Espinosa, Martin-Suarez, Lara-Vasquez, Montero, Muro- García, Fernandez, Encinas-Pérez and Fuentealba. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Pablo Fuentealba, Pontificia Universidad Católica de Chile, Santiago, Chile
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.